NCT02106572 2025-07-23
TIM
Abnoba Gmbh
Phase 3 Active not recruiting
Clinical Trials
3 trialsNCT02007005 2015-05-06
Maximum Tolerable Concentration of abnobaVISCUM Fraxini Intravesically in Patients With Superficial Bladder Cancer
Abnoba Gmbh
Phase 1/2 Completed
NCT02191540 2014-07-23
Efficacy and Safety Study of Abnoba Viscum F 20mg in Malignant Pleural Effusion Patients
Abnoba Korea
Phase 3 Completed